Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 study of ACE910 in healthy volunteers and hemophilia A patients

Trial Profile

Phase 1 study of ACE910 in healthy volunteers and hemophilia A patients

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 12 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Emicizumab (Primary)
  • Indications Haemophilia A
  • Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
  • Sponsors Chugai Pharmaceutical

Most Recent Events

  • 05 Jun 2020 Results (n=389) of a population pharmacokinetics and exploratory exposure analysis from six clinical studies: HAVEN1, HAVEN2, HAVEN3, HAVEN4, JapicCTI-121934 and JapicCTI-132195 published in the Clinical Pharmacokinetics
  • 26 May 2016 Results (n=18) published in the New England Journal of Medicine
  • 26 May 2016 Results of 18 patients with haemophilia A were published in a Chugai Pharmaceutical media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top